![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
October 17, 2024
The changes aim to alleviate scheduling difficulties during the randomization step, and they introduce the new tumor test for this phase 2 trial testing radiotherapy with or without chemotherapy
August 25, 2023
This phase 3 study of oligometastatic head and neck cancer is exploring whether it is more effective to add radiation therapy to standard immunotherapy in patients with stable disease after initial chemotherapy plus immunotherapy
December 20, 2022
This phase 2 study is examining whether the addition of cisplatin to PORT will provide a survival benefit to certain patients with stage 3/4 squamous cell carcinoma of the head and neck
January 26, 2022
This phase 2/3 study is exploring new treatment approaches for patients with recurrent and metastatic head and neck squamous cell carcinoma
August 17, 2021
This phase II trial is comparing adjuvant treatment with either reirradiation plus pembrolizumab, pembrolizumab monotherapy, or reirradiation with platinum chemotherapy